Tentative Outline

Special Issue for CURRENT DRUG DISCOVERY TECHNOLOGIES

Guess Editor: Antonio Gualberto

DEVELOPMENT OF NOVEL AGENT TARGETING THE INSULIN AND INSULIN-LIKE GROWTH FACTOR RECEPTOR PATHWAYS

Aims & Scope:

Preclinical evidence that targeting the IGF-IR and/or the IR may be useful in cancer treatment has been accumulating for almost two decades. Efforts to develop drugs began in the late 1990s, and initial data from clinical trials were reported in 2006. Targeting these receptors has potential relevance to many tumor types, and experience to date has justified expanded clinical studies in many areas of clinical need. More than two dozen drug candidates have been developed and clinical trials are underway for at least 12 of these. Early clinical trials reveal an acceptable safety profile together with evidence that the receptors can be successfully targeted. With more than 70 trials involving a variety of drug candidates, the IGF-IR is becoming one of the most intensively investigated molecular targets in oncology. Early results justify the continuation of ongoing research across a broad range of cancer indications. This special issue of Current Drug Discovery Technologies will discuss the biological rationale for targeting these receptors, the potential advantages and disadvantages of coreceptor targeting versus selective inhibition, key findings in the most advanced drug programs, and the co-development of molecular diagnostics.

Key words:

Insulin, IGF-1, IGF-2, IR, IGF-1R, IGF-IR

Subtopics:

1. Editorial (A Gualberto)
2. The IGF-IR and IR pathways and their role in cancer (M Pollak)
3. Monoclonal antibodies against the IGF-IR (A Gualberto)
4. Dual IGF-IR and IR inhibition (M Gottardis)
5. Biomarker of the safety and efficacy of IGF-IR/IR inhibition (M Hixon)

Schedule:

Manuscript submission deadline: March 2012
Peer Review Due: June 2012
Revision Due: August 2012
Notification of acceptance by the Guest Editor: October 2012
Final manuscripts due: December 2012